[
  {
    "ts": null,
    "headline": "Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?",
    "summary": "BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.",
    "url": "https://finnhub.io/api/news?id=79cb6c8e54c3a18c89342c6dd2cd780fcf49c21e607953c6a149216bfd5d1b67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763662200,
      "headline": "Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?",
      "id": 137566502,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.",
      "url": "https://finnhub.io/api/news?id=79cb6c8e54c3a18c89342c6dd2cd780fcf49c21e607953c6a149216bfd5d1b67"
    }
  },
  {
    "ts": null,
    "headline": "VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug",
    "summary": "Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.",
    "url": "https://finnhub.io/api/news?id=98c70c7c5eeab834aba20473a0aa990bd63730604dc53e9390a9531a7403f531",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763656200,
      "headline": "VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug",
      "id": 137562927,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.",
      "url": "https://finnhub.io/api/news?id=98c70c7c5eeab834aba20473a0aa990bd63730604dc53e9390a9531a7403f531"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Gives Up on High-Yield Stocks",
    "summary": "When the AI bubble bursts, Altria will look like a pretty good investment again. It has paid out billions in dividends over the years, and that is unlikely to stop.",
    "url": "https://finnhub.io/api/news?id=224feae16093021a262d1f3a525e0797fe4aa7aefd8e2a11a5c1f9eaed1acbff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763651756,
      "headline": "Wall Street Gives Up on High-Yield Stocks",
      "id": 137556199,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "When the AI bubble bursts, Altria will look like a pretty good investment again. It has paid out billions in dividends over the years, and that is unlikely to stop.",
      "url": "https://finnhub.io/api/news?id=224feae16093021a262d1f3a525e0797fe4aa7aefd8e2a11a5c1f9eaed1acbff"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer's 6.9%-Yielding Dividend Still Safe?",
    "summary": "The company's earnings fell by 21% last quarter.",
    "url": "https://finnhub.io/api/news?id=e94c535f9460fa4ad48a1ac6e8c268bf175f2a6c2ec90760051ca7f84f730ce0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763649000,
      "headline": "Is Pfizer's 6.9%-Yielding Dividend Still Safe?",
      "id": 137556556,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The company's earnings fell by 21% last quarter.",
      "url": "https://finnhub.io/api/news?id=e94c535f9460fa4ad48a1ac6e8c268bf175f2a6c2ec90760051ca7f84f730ce0"
    }
  },
  {
    "ts": null,
    "headline": "Fighting Cancer With 'Smart Bombs.' What New Treatments Mean For Wall Street.",
    "summary": "Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.",
    "url": "https://finnhub.io/api/news?id=b8a3aecd9b654a7d44551c2604c3f702f4d949c1fadcc14bcd574f85db55374b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763643652,
      "headline": "Fighting Cancer With 'Smart Bombs.' What New Treatments Mean For Wall Street.",
      "id": 137556388,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.",
      "url": "https://finnhub.io/api/news?id=b8a3aecd9b654a7d44551c2604c3f702f4d949c1fadcc14bcd574f85db55374b"
    }
  },
  {
    "ts": null,
    "headline": "This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.",
    "summary": "For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date.  It’s a challenge that  Bristol Myers Squibb  is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022.  Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.",
    "url": "https://finnhub.io/api/news?id=095930a75826d0aee56911bca29526d07044581e6ef8d98e8f635a494a0c3c96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763643600,
      "headline": "This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.",
      "id": 137556460,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date.  It’s a challenge that  Bristol Myers Squibb  is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022.  Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.",
      "url": "https://finnhub.io/api/news?id=095930a75826d0aee56911bca29526d07044581e6ef8d98e8f635a494a0c3c96"
    }
  },
  {
    "ts": null,
    "headline": "BMO Launches New CDRs With Exposure to U.S. Stocks Including Apple, Intel, Mastercard, Pfizer and Visa",
    "summary": "Bank of Montreal (BMO) announced five new Canadian depositary receipts (CDRs) will begin trading on the Cboe Canada exchange today. The initial offering of these new CDRs has closed.",
    "url": "https://finnhub.io/api/news?id=370e9ac04a9bf8c0c55a31d86511bf7ab9a1b9daf1fd434e8954389e06d27208",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763641800,
      "headline": "BMO Launches New CDRs With Exposure to U.S. Stocks Including Apple, Intel, Mastercard, Pfizer and Visa",
      "id": 137556206,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Bank of Montreal (BMO) announced five new Canadian depositary receipts (CDRs) will begin trading on the Cboe Canada exchange today. The initial offering of these new CDRs has closed.",
      "url": "https://finnhub.io/api/news?id=370e9ac04a9bf8c0c55a31d86511bf7ab9a1b9daf1fd434e8954389e06d27208"
    }
  },
  {
    "ts": null,
    "headline": "White House Touts $270 Billion Worth of Deals at Saudi-palooza",
    "summary": "A day after the White House proclaimed that Saudi Arabia boosted its spring pledge to invest $600 billion in the US to a tidy $1 trillion during Crown Prince Mohammed bin Salman’s visit to Washington, DC, President Donald Trump said companies from both nations inked $270 billion in deals at a US-Saudi business forum.  No timeline was given for Saudi Arabia’s $1 trillion in investments and, while the US-Saudi Investment Forum on Wednesday drew corporate royalty from Chevron, Tesla, Nvidia, Qualcomm, Cisco, General Dynamics, Pfizer and more, it wasn’t immediately clear which companies inked deals.  Trump did say GE Aerospace will “deliver dozens of new engines” while a handful of other pacts, while short on financial details, highlighted some international bargaining.",
    "url": "https://finnhub.io/api/news?id=98b32f34daf388fab79ca9059a69d94244b73562f10fbfbd87fc9c296b4fe6bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763638200,
      "headline": "White House Touts $270 Billion Worth of Deals at Saudi-palooza",
      "id": 137566572,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A day after the White House proclaimed that Saudi Arabia boosted its spring pledge to invest $600 billion in the US to a tidy $1 trillion during Crown Prince Mohammed bin Salman’s visit to Washington, DC, President Donald Trump said companies from both nations inked $270 billion in deals at a US-Saudi business forum.  No timeline was given for Saudi Arabia’s $1 trillion in investments and, while the US-Saudi Investment Forum on Wednesday drew corporate royalty from Chevron, Tesla, Nvidia, Qualcomm, Cisco, General Dynamics, Pfizer and more, it wasn’t immediately clear which companies inked deals.  Trump did say GE Aerospace will “deliver dozens of new engines” while a handful of other pacts, while short on financial details, highlighted some international bargaining.",
      "url": "https://finnhub.io/api/news?id=98b32f34daf388fab79ca9059a69d94244b73562f10fbfbd87fc9c296b4fe6bc"
    }
  },
  {
    "ts": null,
    "headline": "$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield",
    "summary": "Discover 5 undervalued large-cap health care stocks using a proven screening method.",
    "url": "https://finnhub.io/api/news?id=d057abb57ab8f45949785205029293c9073aa0bb6830b40b53701c1728a2537a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763637427,
      "headline": "$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield",
      "id": 137557117,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487494602/image_1487494602.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover 5 undervalued large-cap health care stocks using a proven screening method.",
      "url": "https://finnhub.io/api/news?id=d057abb57ab8f45949785205029293c9073aa0bb6830b40b53701c1728a2537a"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis (ZTS): Buy, Sell, or Hold Post Q3 Earnings?",
    "summary": "Zoetis’s stock price has taken a beating over the past six months, shedding 28.6% of its value and falling to a new 52-week low of $116.88 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.",
    "url": "https://finnhub.io/api/news?id=601ad88fcc32c206cfc1a3b6f840ee35e99ac364de75f831e558ef899cfb2318",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763611355,
      "headline": "Zoetis (ZTS): Buy, Sell, or Hold Post Q3 Earnings?",
      "id": 137554153,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Zoetis’s stock price has taken a beating over the past six months, shedding 28.6% of its value and falling to a new 52-week low of $116.88 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.",
      "url": "https://finnhub.io/api/news?id=601ad88fcc32c206cfc1a3b6f840ee35e99ac364de75f831e558ef899cfb2318"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too?",
    "summary": "Pfizer is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech. Have the good days finally come to an end?",
    "url": "https://finnhub.io/api/news?id=b019c194f58cbefa225cbacded2f9a285a6d8bec304882635981489ac068620a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763606547,
      "headline": "Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too?",
      "id": 137554154,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech. Have the good days finally come to an end?",
      "url": "https://finnhub.io/api/news?id=b019c194f58cbefa225cbacded2f9a285a6d8bec304882635981489ac068620a"
    }
  }
]